CTOs on the Move

Med-Valu

www.medvalu.com

 
Med-Valu, Inc. is a Dublin, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.medvalu.com
  • 485 Metro Pl S Ste 200
    Dublin, OH USA 43017
  • Phone: 614.684.2360

Executives

Name Title Contact Details

Similar Companies

Evanston Regional Hospital

Evanston Regional Hospital is your community healthcare provider; a 42-bed facility with complete inpatient and outpatient care. We believe in the power of people to create great care. We`re more than 50 healthcare professionals strong. We are a Joint Commission accredited facility. And we work hard every day to be a place of healing, caring and connection for patients and families in the community we call home.

InSight Telepsychiatry

InSight is the leading national telepsychiatry service provider organization with a mission to transform access to behavioral health care through innovative applications of technology. InSight has 20 years of experience with telepsychiatry and services hundreds of organizations across the nation with its on-demand, scheduled, connected services and Inpathy divisions.

SciTec

SciTec is a company that provides cutting edge advancements for defense, security, and civil affairs. Their team is committed to delivering advanced sensor systems, data processing algorithms, and testing equipment for defense, national security, and c...

Valley Health

Valley Health is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Winchester, VA. To find more information about Valley Health, please visit www.valleyhealthlink.com

Plasmatech Biopharmaceuticals

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.